Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Y-Mabs Therapeutics Inc (NQ: YMAB )

13.28 +0.30 (+2.31%)
Streaming Delayed Price Updated: 11:21 AM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37,766
Open 13.18
Bid (Size) 13.28 (2)
Ask (Size) 13.35 (4)
Prev. Close 12.98
Today's Range 13.09 - 13.39
52wk Range 4.600 - 20.90
Shares Outstanding 43,882,638
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+93.30%
+93.30%
1 Month
+13.02%
+13.02%
3 Month
-10.93%
-10.93%
6 Month
+38.48%
+38.48%
1 Year
+85.22%
+85.22%

More News

Read More
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
Via Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 29, 2024
Via Benzinga
Earnings Outlook For Y-mAbs Therapeutics
Via Benzinga
Earnings Preview For Y-mAbs Therapeutics
Via Benzinga
4 Analysts Have This to Say About Y-mAbs Therapeutics
Via Benzinga
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Analyst Expectations for Y-mAbs Therapeutics's Future
Via Benzinga
Where Y-mAbs Therapeutics Stands With Analysts
Via Benzinga
B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
Via Investor's Business Daily
Micro Marvel - Y-Mabs Therapeutics
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Earnings Scheduled For May 8, 2023
Via Benzinga
Earnings Scheduled For November 13, 2023
Via Benzinga
Earnings Scheduled For August 10, 2023
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.